AVGO vs PFE: Which Is the Better Buy?

Side-by-side comparison of Broadcom Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-06.
Broadcom Inc. · Technology
$379.86
-41.0% upside to fair value
Grade C High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value (+2.8%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric AVGO PFE
Current Price $379.86 $25.22
Fair Value Estimate $223.93 $25.92
Upside to Fair Value -41.0% +2.8%
Market Cap $1,806.8B $143.7B
Forward P/E 61.3x 19.2x
EV / EBITDA 44.1x 12.3x
Price / Sales 23.9x 2.3x
Price / FCF 55.2x 15.2x
Revenue Growth YoY +47.9% +5.4%
Gross Margin 67.0% 69.3%
Operating Margin 43.7% 23.4%
Return on Equity 36.4% 8.4%
Dividend Yield 0% 0%
FCF Yield 1.81% 6.6%
Analyst Consensus Strong Buy Hold
Investment Thesis
AVGO — Broadcom Inc.
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a business split nearly evenly between these two segments. The company benefits from a durable competitive moat driven by customer concentration in mission-critical infrastructure, high switching costs, and a broad portfolio spanning semiconductors and infrastructure software. Broadcom h…
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
Metric AVGO PFE
Zone Low $167.95 $19.44
Zone High $190.34 $22.03
In Buy Zone? No No
← AVGO Research    PFE Research →    All Research